Correlation of Urine Loss after Catheter Removal and Early Continence in Men Undergoing Radical Prostatectomy.
functional outcome
incontinence
pad-test
radical prostatectomy
urinary incontinence
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
15 11 2021
15 11 2021
Historique:
received:
10
10
2021
revised:
07
11
2021
accepted:
13
11
2021
entrez:
13
12
2021
pubmed:
14
12
2021
medline:
24
3
2022
Statut:
epublish
Résumé
To determine the correlation between urine loss in PAD-test after catheter removal, and early urinary continence (UC) in RP treated patients. Urine loss was measured by using a standardized, validated PAD-test within 24 h after removal of the transurethral catheter, and was grouped as a loss of <1, 1-10, 11-50, and >50 g of urine, respectively. Early UC (median: 3 months) was defined as the usage of no or one safety-pad. Uni- and multivariable logistic regression models tested the correlation between PAD-test results and early UC. Covariates consisted of age, BMI, nerve-sparing approach, prostate volume, and extraprostatic extension of tumor. From 01/2018 to 03/2021, 100 patients undergoing RP with data available for a PAD-test and early UC were retrospectively identified. Ultimately, 24%, 47%, 15%, and 14% of patients had a loss of urine <1 g, 1-10 g, 11-50 g, and >50 g in PAD-test, respectively. Additionally, 59% of patients reported to be continent. In multivariable logistic regression models, urine loss in PAD-test predicted early UC (OR: 0.21 vs. 0.09 vs. 0.03; for urine loss 1-10 g vs. 11-50 g vs. >50 g, Ref: <1 g; all Urine loss after catheter removal strongly correlated with early continence as well as a severity in urinary incontinence.
Sections du résumé
BACKGROUND
To determine the correlation between urine loss in PAD-test after catheter removal, and early urinary continence (UC) in RP treated patients.
METHODS
Urine loss was measured by using a standardized, validated PAD-test within 24 h after removal of the transurethral catheter, and was grouped as a loss of <1, 1-10, 11-50, and >50 g of urine, respectively. Early UC (median: 3 months) was defined as the usage of no or one safety-pad. Uni- and multivariable logistic regression models tested the correlation between PAD-test results and early UC. Covariates consisted of age, BMI, nerve-sparing approach, prostate volume, and extraprostatic extension of tumor.
RESULTS
From 01/2018 to 03/2021, 100 patients undergoing RP with data available for a PAD-test and early UC were retrospectively identified. Ultimately, 24%, 47%, 15%, and 14% of patients had a loss of urine <1 g, 1-10 g, 11-50 g, and >50 g in PAD-test, respectively. Additionally, 59% of patients reported to be continent. In multivariable logistic regression models, urine loss in PAD-test predicted early UC (OR: 0.21 vs. 0.09 vs. 0.03; for urine loss 1-10 g vs. 11-50 g vs. >50 g, Ref: <1 g; all
CONCLUSIONS
Urine loss after catheter removal strongly correlated with early continence as well as a severity in urinary incontinence.
Identifiants
pubmed: 34898569
pii: curroncol28060399
doi: 10.3390/curroncol28060399
pmc: PMC8628712
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4738-4747Références
N Engl J Med. 2012 Jul 19;367(3):203-13
pubmed: 22808955
Am J Mens Health. 2020 Sep-Oct;14(5):1557988320957535
pubmed: 32938266
World J Urol. 2021 Mar;39(3):771-777
pubmed: 32361875
Eur Urol. 2020 Jul;78(1):e14-e15
pubmed: 32349936
N Engl J Med. 2016 Oct 13;375(15):1415-1424
pubmed: 27626136
Urol Oncol. 2014 Apr;32(3):297-302
pubmed: 24332640
Eur Urol Focus. 2017 Dec;3(6):615-620
pubmed: 28869202
Int Urol Nephrol. 2021 Jul;53(7):1297-1303
pubmed: 33606155
Eur Urol. 2015 Nov;68(5):899-905
pubmed: 26293181
Front Surg. 2019 Oct 25;6:60
pubmed: 31709260
Eur Urol. 2014 Jul;66(1):138-44
pubmed: 24411279
Minerva Urol Nefrol. 2020 Oct;72(5):640-641
pubmed: 32993276
Urol Oncol. 2015 May;33(5):203.e11-8
pubmed: 25814146
Prostate Int. 2018 Sep;6(3):94-98
pubmed: 30140658
Eur Urol Focus. 2019 Sep;5(5):823-830
pubmed: 29759661
Urologia. 2011 Oct;78 Suppl 18:35-8
pubmed: 22101550
J Urol. 2014 Oct;192(4):1155-61
pubmed: 24727062
BJU Int. 2016 Aug;118(2):193-204
pubmed: 27087414
Urol Oncol. 2021 Aug 26;:
pubmed: 34456124
Eur Urol. 2007 Jul;52(1):178-85
pubmed: 17222961
Eur Urol. 2011 Aug;60(2):320-9
pubmed: 21458913
Eur Urol. 2012 Sep;62(3):405-17
pubmed: 22749852
BJU Int. 2019 Jun;123(6):1031-1040
pubmed: 30927303
Eur Urol. 2017 Jun;71(6):936-944
pubmed: 27720536
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
BMC Urol. 2019 May 6;19(1):32
pubmed: 31060521
Eur Urol. 2017 Jun;71(6):848-850
pubmed: 27743754
BJU Int. 2019 Sep;124(3):477-486
pubmed: 30801887
Eur Urol Focus. 2021 Jan;7(1):95-101
pubmed: 30905598